Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Sweden's success factors in the development of biological drugs

Wed 17 Mar 2021 at 09:00-11:35

Biological drugs are an area in rapid development where Sweden has a leading position. In the continued development, collaboration and innovative capacityare needed, among other things. Welcome to explore the future possibilities in biological drugs together with important actors during two webcast seminars in March 2021. The first seminar is about Sweden's success factors in the development of biological drugs.

This web page has been machine translated. If there are any uncertainties, please refer to the Swedish text.

Sweden's success factors in the development of biological drugs

Biological drugs are a rapidly growing field. Not least, digitalisation opens up great opportunities. Thanks to important investments, Sweden is in the lead as the area continues to develop.

You will meet important actors from, among others, the government's Life Science-kontor, companies, research and financiers. They share their perspectives and talk in a panel discussion on how Sweden can take advantage of important success factors and continue to be involved in leading development. There will be room to ask questions and contribute thoughts in the discussion.

Read more about the second seminar on March 24 on future opportunities with biological drugs in health care


Moderator: Karin Aase, Vinnova

9.00-9.45 Introduction to the Biological Medicines program and the Swedish Life Science-strategin

  • Background and status of Life Science-strategin, Jenni Nordborg, Government Offices
  • Summary of results so far in the program Biological drugs, Mats Jarekrans, Vinnova
  • About the program and related activities:
    Madeleine Durbeej-Hjalt, Swedish Research Council
    Lars Hammarström, Vinnova


9.55-10.45 Future opportunities with biological drugs

  • Future opportunities with biological drugs, Mathias Uhlén, KTH
  • AstraZeneca's view of the program, the field of biological drugs and the future, Anna Sandström, AstraZeneca
  • Industrifonden's view of and work with research and innovation on biological drugs, Bita Sehat, Industrifonden


10.55-11.25 Panel Discussion

11.25 Summary

During breaks and after the seminar is the opportunity to explore digital print by ongoing project within the program Biologics.

The seminars are arranged within the framework of Vinnova's programme Biological Medicines

The program has over the years 2016-2019 made four calls that led to the funding of 30 project including three centers, with 270 million.

Read more about the projects within Vinnova's programme Biological drugs

Sometimes we photograph or video record our activities. If you don't want to participate in photos or videos, please let us when you arrive.


Mats Jarekrans

Programme Director for Berzelii Centra

+46 8 473 31 85

Others also read

Last updated 27 January 2021

Page statistics